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Abstract The WT1 gene is a tumor suppresser gene for Wilms' 
tumor (WT). Inactivation of both alleles has been proposed as the 
cause of WT. We encountered a patient with Denys-Drash syn- 
drome associated with WT whose WT1 gene had a homozygous 
point mutation not only in WT but also in renal tissue adjacent 
to the WT and in the germline. These findings indicate that 
factor(s) other than the loss of WT1 are required for WT to 
develop. 
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1. Introduction 
Wilms' tumor (WT) or nephroblastoma is a childhood kid- 
ney tumor which is thought o arise from cells of the metaneph- 
ric blastema, a fetal kidney structure. Based on cytogenetic and 
molecular genetic studies, there are at least three responsible 
loci for this tumor [1]. Only one of these genes, WT1, has been 
identified in the distal l lp13 region [2,3]. The product of this 
gene is a transcriptional factor with four zinc fingers, and it 
binds to a specific DNA sequence [2,4]. Because xpression of 
WT1 is limited to the developing lomeruli of the kidney, it is 
thought o have a functional role in renal organogenesis [5]. On 
the other hand, a mutation occurs in the WT1 gene, loss of 
normal regulation of proliferation, leading to tumor formation. 
The existence of intragenic mutations of the gene, including 
point mutations found in the DNA from WT, supports this 
hypothesis [6-12]. A case of Denys-Drash syndrome associated 
with WT is inconsistent with this concept, however, because we 
found the same homozygous mutation in the germline, the 
kidney and in tumor tissue. This finding forces us to reconsider 
the role of the WT1 gene in tumorigenesis. 
2. Materials and methods 
2.1. Genomic DNA isolation 
Genomic DNAs were prepared from WT and renal tissue adjacent 
to the WT (the tumor-free state confirmed by microscopic examination) 
using the SDS-proteinase K method with slight modification, as de- 
scribed in our previous report [9]. To extract DNA from peripheral 
leukocytes, 10 ml of whole blood was lysed and centrifuged. The sedi- 
ment was then subjected to the same procedure as the tissues. 
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2.2. DNA blot analysis and PCR-SSCP analysis [12] 
DNA blot analysis [13] and PCR-SSCP analysis [14] were performed 
as previously described. To identify mutations in WT1 exon 8, we 
amplified genomic DNA from white blood cells (WBCs), non-tumor 
renal tissue, and WT with the following oligonucleotides: 8-S (forward): 
5'-AGATCCCCTTTTCCAGTATC-3' and 8-A (reverse): 5'-GCCAG- 
CAATGAGAAGTGAAC-3'. 
2.3. DNA sequences 
PCR was performed with 1 pg of genomic DNA in a total volume 
of 100 pl using the unlabeled primers described above. The amplified 
mixture was extracted with phenol/chloroform, passed through aMicro 
Spin column S-400 (Pharmacia) and precipitated with ethanol. For 
direct sequencing, half of the reaction mixture was used for dideoxy 
sequencing using an AutoCycle kit (Pharmacia) and FITC-labeled 
primer 8-S or 8-A. The products were analyzed on 6% polyacrylamide 
gels containing 7 M urea using an A.L.F. DNA sequencer (Pharmacia). 
PCR products were also sequenced after cloning using the p-GEM-T 
vector system (Stratagene) with the same kit. 
3. Results 
3.1. Patient description and pathological findings 
The patient was a girl who was 1 year and 1 month old at 
the time of admission. Her chief complaint was abdominal 
distention. Intravenous pyelography, computerized tomogra- 
phy and ultrasound examination revealed a tumor occupying 
the lower half of her left kidney. She also had proteinuria. Left 
nephrectomy was performed and was followed by chemother- 
apy. As a result of histological examination, the tumor was 
classified as a WT, triphasic type. Most of the glomeruli showed 
focal, segmental mesangial sclerosis (Fig. 1). Global sclerosis 
of the mesangium was also detected in some glomeruli. These 
histological findings were consistent with Denys-Drash syn- 
drome. 
3.2. PCR-SSCP analysis of  WT1 of the patient 
The PCR-SSCP method was used to screen for mutations in 
WT1 exons 7, 8, 9, 10 (zinc finger domain I-IV). We could not 
find any mobility shift in exons 7, 9 or 10 (data not shown). We 
analyzed the exon 8 PCR products from the genomic DNA of 
WT, renal tissue adjacent to tumor tissue and WBC. The results 
clearly demonstrated analtered migrating fragment (Fig. 2). No 
fragments comigrated with the unaffected human placental 
DNA. 
3.3. Sequence analysis of WT1 
Direct sequencing of the PCR product on exon 8 from the 
WT and renal tissue revealed a G to A transition at nucleotide 
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Fig. 1. Histology of the renal tissue adjacent to the Wilms' tumor of the 
case (PAM stain) showing features of diffuse mesangial sclerosis. 
position 1064 (Fig. 3). This mutation results in the substitution 
of Tyr 355 for Cys. The same sequence was obtained with both 
the forward and with the reverse primer. To determine whether 
this mutation was present in the germline, we sequenced the 
PCR product of a DNA sample from the patient's WBCs. All 
of the nucleotide sequences obtained coincided with those from 
the kidney and WT. 
3.4. DNA blot analysis 
We performed DNA blot analysis to confirm that one of the 
WT1 genes had not been deleted. No gross deletion or duplica- 
tion of WT1 was found (Fig. 4). The 3.1 kb fragments, which 
include exon 8, of the DNA from the patient issues had the 
same density as the normal control. Because our DNA blot 
analysis could detect loss of one allele [13], there are two alleles 
containing exon 8. Judging from this finding and the results of 
PCR-SSCP and sequence analysis, the DNA samples from this 
patient exhibited the same point mutation on exon 8 of both 
WT1 alleles. 
NTKW 
Fig. 2. PCR-SSCP analysis of WT1 exon 8. The forward primer was 
radiolabeled with 32P. The amplified sense fragments (indicated by 
arrowheads) of genomic DNA from Wilms' tumor of the case (T), 
kidney (K) and WBCs (W) moved to downward positions from that of 
the control unaffected human placental DNA (N). 
4. Discussion 
According to the results of PCR-SSCP and sequence analy- 
sis, the WT1 gene of the patient carried with a point mutation 
of exon 8. No abnormalities was shown by DNA blot analysis 
which can distinguish one copy and two copies of DNA se- 
quence per single cell [13]; the density of the fragments contain- 
ing exon 8 were not different from that of normal control. From 
these results, the Wilms' tumor, kidney and WBCs of the pa- 
tient have two WT1 alleles with the same point mutation. 
Namely, the mutation in exon 8is homozygous. As the same 
abnormality was found in different tissues, the mutation is 
likely to be present in the germline. Sakai et al. examined the 
WT1 gene in the DNA isolated from WBCs of the patient and 
her mother, though they did not analyzed the DNA from pa- 
tient's kidney tissue or Wilms' tumor. They found the same 
point mutation as ours in the patient's WBCs although her 
mother had no mutation in WT1 including exon 8 [15]. Unfor- 
tunately, the patient's father refused any DNA analysis. Since 
themajority of patients with the syndrome have been shown to 
carry de novo mutations, perhaps the patient's father did not 
have the mutation. The most probable xplanation is as fol- 
lows. The first point mutation had occurred uring oogenesis 
or spermatogenesis. Just after fertilization the second episode 
occurred, which might be gene conversion transferring the 
point mutation to the opposite allele. Because the case that had 
the 16146 to A conversion has not been reported except his 
case, it is not likely that the identical rare mutation accidentally 
arose separately. We could not deny the possibility, however, 
that the mutation had been transmitted from the patient's fa- 
ther, for we [14] and Coppes et al. [16] identified the patients 
having the WT1 mutation observed in Denys-Drash syndrome 
without any signs or symptoms of the syndrome. 
Conversion of the Cys residue chelating the zinc in zinc finger 
I was also detected in another WT [10]. Because this Cys residue 
is thought o be one of the key amino acids that chelate zinc 
and give rise to the finger-like protrusion binding to target 
DNAs in the second zinc finger [17,18], the homozygous muta- 
tion in the patient should greatly affect he function of the WT1 
products. There is a possibility that there is another mutation 
in the patient's WT1 gene because we analyzed only WT1 exon 
7-10, although it will be contribute weaker effects on Wilms' 
tumorigenesis. 
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Fig. 3. Direct sequence analysis of WT1 exon 8 with A.L.F. DNA 
sequencer (described in section 2). The genomic DNAs from Wilms' 
tumor, kidney and WBCs of the case had the same point mutation, 
replacement G to A. 
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Fig. 4. DNA blot analysis of WT1 (probe EcoRI fragment of WT33 [2]). 
Numbers indicating sizes (kb) of fragments. All fragment of DNA 
samples from patient's tumor (T), kidney (K) and WBCs (W) were same 
intensity as those of the control unaffected human placental DNA (N). 
The underscored 3.1 kb fragments contain WT1 exon 8. 
DNA from both WTs and normal tissue has been analyzed 
in several studies, and intragenic WT1 mutations have been 
detected [7-12]. In all of these studies, the WT1 gene was mu- 
tated in both alleles in the WTs, but in only one or neither allele 
in normal tissue. These findings uggested that complete loss 
of function of WT1 might be sufficient to cause Wilms' tumors 
[19]. The findings in our patient, however, are incompatible 
with this hypothesis because there were cells in the kidney(s) of 
the patient that had no normal WT1 alleles and did not undergo 
malignant transformation. Therefore, the case reported here is 
an example which refutes the hypothesis tated above, and 
factor(s) in addition to mutation of the WT1 gene is/are needed 
for WT to develop. 
Recently, Park et al. described two cases in which WT and 
nephrogenic rests (considered to be precursor lesions of WT) 
contained the same mutated WT1 gene [20]. This report and 
ours both adopt the same viewpoint regarding the necessity of 
other factor(s) for malignant transformation. They did not, 
however, find mutations of WT1 in the germline. They catego- 
rized the nephrogenic rests as clonal pre-cancerous lesions 
whose formation isthe rate-limiting step in tumorigenesis in the 
'two-hit' model. In contrast, the mutation of WT1 in our pa- 
tient is not likely to be a rate-limiting step for malignant trans- 
formation because the transversion of the critical amino-acid 
residue had probably been present in the germline. 
A candidate for the factor required for development of WT, 
is an additional tumor suppresser gene located at 1 lp15. Inter- 
actions between WT1 and a putative suppresser gene on 1 lp15 
in tumorigenesis have been suggested [6]. Another possibility 
is co-operation between mutated WT1 and certain oncogenes. 
Haber et al. have reported the cooperation ofa dominant WT1 
mutation with the viral oncogene E1A in the transformation f 
primary kidney cells [21]. 
In conclusion, mutation of both WT1 alleles is not sufficient 
to cause WT to develop. Additional factor(s) remain to be 
identified to clarify the mechanisms of the development of 
Wilms' tumor. 
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